BNP Paribas Financial Markets Acquires 99,685 Shares of Integra LifeSciences Holdings Co. (NASDAQ:IART)

BNP Paribas Financial Markets boosted its position in Integra LifeSciences Holdings Co. (NASDAQ:IART - Free Report) by 824.5% during the third quarter, according to its most recent 13F filing with the SEC. The firm owned 111,775 shares of the life sciences company's stock after acquiring an additional 99,685 shares during the period. BNP Paribas Financial Markets owned 0.14% of Integra LifeSciences worth $2,031,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Blue Trust Inc. grew its holdings in Integra LifeSciences by 100.5% during the 2nd quarter. Blue Trust Inc. now owns 886 shares of the life sciences company's stock valued at $26,000 after buying an additional 444 shares in the last quarter. CWM LLC boosted its stake in Integra LifeSciences by 50.8% in the second quarter. CWM LLC now owns 1,262 shares of the life sciences company's stock worth $37,000 after buying an additional 425 shares in the last quarter. KBC Group NV boosted its stake in Integra LifeSciences by 65.2% in the third quarter. KBC Group NV now owns 2,839 shares of the life sciences company's stock worth $52,000 after buying an additional 1,120 shares in the last quarter. Northwest Investment Counselors LLC purchased a new stake in Integra LifeSciences in the third quarter worth approximately $73,000. Finally, Canada Pension Plan Investment Board purchased a new stake in Integra LifeSciences in the second quarter worth approximately $114,000. 84.78% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several analysts have weighed in on the company. Citigroup boosted their price objective on Integra LifeSciences from $16.00 to $22.00 and gave the company a "sell" rating in a research report on Tuesday, November 5th. Bank of America reduced their price target on Integra LifeSciences from $26.00 to $18.00 and set an "underperform" rating on the stock in a research note on Monday, October 7th. Morgan Stanley assumed coverage on Integra LifeSciences in a research note on Monday, December 2nd. They issued an "underweight" rating and a $20.00 price target on the stock. BTIG Research raised Integra LifeSciences from a "sell" rating to a "neutral" rating in a research note on Monday, October 7th. Finally, Truist Financial reduced their price target on Integra LifeSciences from $26.00 to $21.00 and set a "hold" rating on the stock in a research note on Monday, October 14th. Three equities research analysts have rated the stock with a sell rating, five have assigned a hold rating and one has assigned a buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of "Hold" and an average price target of $23.00.

Integra LifeSciences Price Performance

NASDAQ IART traded up $0.24 during trading on Friday, hitting $24.10. 415,162 shares of the stock traded hands, compared to its average volume of 789,292. The company has a market capitalization of $1.86 billion, a P/E ratio of -267.75, a price-to-earnings-growth ratio of 0.82 and a beta of 1.15. The firm has a 50-day simple moving average of $21.44 and a 200-day simple moving average of $23.88. The company has a quick ratio of 0.73, a current ratio of 1.20 and a debt-to-equity ratio of 0.79. Integra LifeSciences Holdings Co. has a 12-month low of $16.81 and a 12-month high of $45.42.

Integra LifeSciences (NASDAQ:IART - Get Free Report) last released its quarterly earnings results on Monday, November 4th. The life sciences company reported $0.41 earnings per share for the quarter, beating the consensus estimate of $0.39 by $0.02. The business had revenue of $380.80 million during the quarter, compared to analysts' expectations of $375.81 million. Integra LifeSciences had a positive return on equity of 12.35% and a negative net margin of 0.42%. The firm's revenue for the quarter was down .4% compared to the same quarter last year. During the same quarter last year, the business posted $0.76 EPS. As a group, analysts predict that Integra LifeSciences Holdings Co. will post 2.45 EPS for the current year.

Insider Transactions at Integra LifeSciences

In other news, EVP Michael J. Mcbreen sold 1,700 shares of Integra LifeSciences stock in a transaction that occurred on Monday, December 2nd. The stock was sold at an average price of $24.16, for a total value of $41,072.00. Following the completion of the transaction, the executive vice president now owns 56,182 shares in the company, valued at approximately $1,357,357.12. The trade was a 2.94 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 3.10% of the company's stock.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.